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2007). First, we calculated the age-adjusted hospital admission rates for adults 18      
years and older, based on the United Nations Standard Population. Second, we 
adjusted the avoidable hospitalization rates to the prevalence of corresponding condi-
tions. That was possible for three AHCs for which prevalence was documented: 
asthma, hypertension, and diabetes. To compare primary care practices, we tracked 
and followed, patients treated for pneumonia, pyelonephritis and asthma in the IMS 
DiseaseAnalyser® database based on panels of general practitioners in France and the    
UK. RESULTS: The age-adjusted and the prevalence-adjusted avoidable hospitaliza-
tion rates were simultaneously higher by 24% and 67% for the UK compared to 
France. When comparing the primary care practice in both countries for the same 
pathologies, we found that French and British GPs prescribe similarly according to            
therapeutic recommendations. The only difference we could observe was in the access 
to the primary care providers where the French health system organization makes it 
a lot easier to consult a physician and get appropriate primary care. CONCLUSIONS: 
According to the Avoidable Hospitalization indicator, the quality of primary care is 
better in France than in the UK. It allowed avoiding 18.5% of the hospitalizations for 
the 12 AHCs in 2006 which represents almost 117,000 hospitalizations. Could a         
higher quality of primary care reduce hospital expenditures?
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OBJECTIVES: For rare diseases it may be impossible to generate data from random-
ized trials to inform health policy decisions within a reasonable timeframe. Enzyme 
replacement therapies for rare diseases due to inherited metabolic enzyme deﬁciency 
provide an example of this dilemma. The Ontario Public Drug Program convened the 
Drugs for Rare Diseases Working Group (DRD WG) to develop a framework for 
assessing these drugs in a fair, transparent, and consistent way. METHODS: The DRD 
WG developed terms of reference expecting that the ideal policy product would be 
transparent, consistent, and address unique aspects of treatment of a speciﬁc rare 
condition while being adaptable to other dissimilar conditions. The perspective was 
that of a public payer addressing requests for funding generated for a speciﬁc drug, 
and included respect for the principles of “accountability for reasonableness” of 
Daniels and Sabin. Based on these principles, a consensus process was developed and 
tested by case study. RESULTS: No existing policy processes for potential adoption 
were identiﬁed, so a 7-step framework was systematically drafted: 1) Conﬁrm condi-
tion is truly “rare”; 2) Understand the disease; 3) Understand potential value of can-
didate drug; 4) Estimate clinical effectiveness of candidate drug; 5) Estimate cost 
implications and generate a funding recommendation; 6) Review evaluation with 
disease experts and stakeholders; and 7) Reassessment. The framework has been tested 
with 2 case studies: idursulfase for mucopolysaccharidosis II and alglucosidase for 
glycogen storage disease II. Estimation of clinical effectiveness was done using decision 
modeling. Funding recommendations for both drugs were generated. CONCLU-
SIONS: This policy framework attempts to address the policy challenges of funding 
drugs for rare diseases by considering available evidence in a thorough and realistic 
manner. It will inevitably require modiﬁcation with experience. This framework will 
be adapted for other drugs in future and may be of value to other policy makers.
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OBJECTIVES: Patient access schemes for novel medicines are increasingly imple-
mented in the UK, being based on linking payment to result (outcome-based) or 
capping cost per patient (ﬁnance-based). However, little is known about what schemes 
are actually being run, how useful they are perceived to be and what are the challenges 
faced. We investigated these questions. METHODS: During this qualitative survey, 
we held in depth, open-ended discussions with senior NHS/NICE representatives (n  
11), academics and health care consultants (n  6), and senior pharmaceutical industry 
representatives (n  7). The focus was on patient access schemes for new drugs imple-
mented in the UK during 2000-mid 2009. RESULTS: Of the 13 schemes identiﬁed, 
most are in oncology (n  9), and ﬁnance-based (n  8) rather than outcome-based; 
seven are included in positive NICE appraisals. Awareness and implementation of 
these schemes are highly variable, albeit less for NICE-endorsed ones. NHS respon-
dents acknowledged theoretical utility of the schemes in reducing uncertainty about 
value for money and (for local stakeholders) shifting some of budget impact risk 
towards the industry. But they saw important challenges: potentially cumbersome 
administrative burden, lack of capabilities to assess real implementation costs, and 
high uncertainty about whether relevant NHS stakeholders actually obtain the ﬁnan-
cial payback. For industry stakeholders, the schemes were essentially a means to obtain 
NICE approval following initial rejection, while preserving a high UK price (crucial 
in the context for international price referencing). A lesser consideration was the 
potential for competitive advantage through, for example, positive perceptions about 
the product and company. CONCLUSIONS: NHS and industry stakeholders generally 
see patient access schemes as beneﬁcial, at least in principle. This approach will likely 
continue for high cost drugs that would otherwise have a cost/QALY marginally over 
the accepted threshold. Adoption of more schemes will depend upon the future capa-
bility of the NHS to accurately monitor their ﬁnancial beneﬁts and implementation 
costs.
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OBJECTIVES: This study investigates the perceptions of Saudi students attending 
American universities towards a new Mandatory Cooperative Health Insurance 
Program (MCHIP) that was introduced recently in Saudi Arabia. METHODS: This 
was a cross-sectional study. Data were collected using e-survey method including all 
2210 Saudi students based on a list provided by the Saudi Cultural Mission at USA. 
Likert scale was employed to measure the students’ expectations of the MCHIP with 
respect to cost, quality, and access of health care; (1  strongly agree to 5  strongly 
disagree). Logistic regression was used to measure the effects of knowledge (knowledge 
of the MCHIP, knowledge of the American health system, and total knowledge of 
health insurance) and students’ expectations of the MCHIP regarding cost, quality 
and access. The response variable was categorized as binary; high knowledge 91), 
while low knowledge (0). Validity and reliability were done. RESULTS: Survey 
response rate was 40.6%. A total of 55.6% agree that cost will be increased while 
19.4% disagree with mean score of 2.45 (SD  1.13). A total 65.3% agree that quality 
is going to be improved, while 8.3% disagree with mean score of 2.5 (SD  0.99); 
56.3% agree that access will be improved, while 15.7% disagree with mean score 2.45 
(SD  1.04). Odds ratio of high knowledge compared to low knowledge was 2.91(P-
Value  0.001) for cost, 1.61. (P-Value  0.461) for quality, and 2.64 (P-Value  
0.203) for access. CONCLUSIONS: Majority expected MCHIP implementation will 
increase total costs, improve quality, and increase access to health care in Saudi 
Arabia. Total knowledge of health insurance had a signiﬁcant effect on students’ per-
ceptions of cost and a non-signiﬁcant effect on their perceptions of quality and access 
to health care. To promote success, the MCHIP should provide affordable and acces-
sible quality health care to the population, based on developed regulations. Awareness 
campaign should be launched.
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OBJECTIVES: Comparisons are often made between the performances of different 
countries’ health care systems. In 2000, the World Health Organisation (WHO) 
attempted to measure the performance of health systems of 191 countries and to create 
league tables of good and bad performers. However, a major assumption of the WHO 
research was that the general public had the same preferences for health care system 
attributes, no matter which country they were based. Our study aims to provide a 
pilot study to evaluate the public health preferences of citizens of the UK and Australia. 
METHODS: Eight attributes were carefully selected to convey information about a 
health care system. These included: life expectancy, infant mortality rates, waiting 
times, degree of choice, direct access to specialist, level of information provided and 
degree of funding from the public. A discrete choice experiment approach was used 
to model to preferences of the individuals. RESULTS: All characteristics affected the 
likelihood a health system would be preferred, with the exception of the additional       
tax contribution levels required to ﬁnance the system. The Australian sample was 
generally willing to forgo a greater number of years of life expectancy for gains related 
to responsiveness; whilst, the UK sample was willing to forgo a greater number of 
years for equity gains. CONCLUSIONS: The preliminary ﬁndings of this pilot study 
suggest some consistency between the health system preferences of two samples 
selected from the UK and Australia. However, they also provide some indication that    
health system exposure may affect the strength of preferences surrounding the attri-
butes that individuals consider to be important for their preferred health system.
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OBJECTIVES: The objective of this study was to compare patient access privileges to 
medicinal products through National Healthcare Reimbursement Systems in Adriatic 
region, namely Slovenia, Croatia, Bosnia and Herzegovina and Serbia. Over the past 
years, in developed countries, major advances have been made in methods and applica-
tion of health technology assessment (HTA). With the exception of Slovenia, other 
countries included in our analysis, have only recently initiated some HTA activities. 
The results of this research shall enable active engagement of national decision makers. 
METHODS: This was a simple country to country comparison of reimbursement lists. 
